SPMED Co., Ltd. is pleased to announce that its innovative medical device, the SPMED™ Genotyping Kit: CYP2D6, has been selected for the "2025 2nd Export-Led Pilot Purchase Program" hosted by the Public Procurement Service (PPS) of Korea. Consequently, we have successfully completed the export of the product to the Indonesian and Vietnamese markets.
This program, a collaborative initiative between the PPS and overseas pilot-user institutions, supports the growth of companies possessing innovative technologies by facilitating local field tests and demonstrations. Through this project, SPMED has supplied its products to major universities in Indonesia and Vietnam, establishing a significant foothold for our pharmacogenetic diagnostic kits in the Southeast Asian precision medicine market.
Project & Product Details
Project Name: 2025 2nd Export-Led Pilot Purchase Program (Public Procurement Service)
Target Markets: Indonesia, Vietnam
Export Product: SPMED™ Genotyping Kit: CYP2D6
The SPMED™ Genotyping Kit: CYP2D6 is an innovative diagnostic tool designed to accurately detect variations in the CYP2D6 gene, which plays a critical role in drug metabolism. This kit enables healthcare providers to offer personalized drug prescriptions tailored to each patient’s genetic profile.
Future Expansion
Building on the results of this pilot program, SPMED plans to secure local clinical data and expand its market presence throughout Southeast Asia. In close cooperation with the Public Procurement Service, we are committed to contributing to the growth of the nation’s innovative industries while leading the way in providing safe and effective personalized treatment solutions to patients worldwide.
We appreciate your continued interest and support as SPMED continues its journey as a global leader in precision medicine.
Thank you.
The Executives and Staff of SPMED Co., Ltd.
